Trial Profile

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-SARS-CoV-2 hyperimmune globulin therapy-Grifols (Primary) ; COVID-2019 immune globulins (Human) (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use
Acronyms INSIGHT-012; OTAC

21 Aug 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2026.
21 Aug 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2026.
06 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com